Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H22ClN3O3 |
| Molecular Weight | 423.892 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(O)CCC(=O)C[C@@H]1N(C(=O)C2=CC=CC=C12)C3=CC=C4C=CC(Cl)=NC4=N3
InChI
InChIKey=ADHYPRBHQVZOTP-SFHVURJKSA-N
InChI=1S/C23H22ClN3O3/c1-23(2,30)12-11-15(28)13-18-16-5-3-4-6-17(16)22(29)27(18)20-10-8-14-7-9-19(24)25-21(14)26-20/h3-10,18,30H,11-13H2,1-2H3/t18-/m0/s1
| Molecular Formula | C23H22ClN3O3 |
| Molecular Weight | 423.892 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:21:51 GMT 2023
by
admin
on
Sat Dec 16 19:21:51 GMT 2023
|
| Record UNII |
DFL6ZK4CGY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
88379561
Created by
admin on Sat Dec 16 19:21:51 GMT 2023 , Edited by admin on Sat Dec 16 19:21:51 GMT 2023
|
PRIMARY | |||
|
1394812-15-7
Created by
admin on Sat Dec 16 19:21:51 GMT 2023 , Edited by admin on Sat Dec 16 19:21:51 GMT 2023
|
PRIMARY | |||
|
153046-24-3
Created by
admin on Sat Dec 16 19:21:51 GMT 2023 , Edited by admin on Sat Dec 16 19:21:51 GMT 2023
|
ALTERNATIVE | |||
|
DFL6ZK4CGY
Created by
admin on Sat Dec 16 19:21:51 GMT 2023 , Edited by admin on Sat Dec 16 19:21:51 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
Its affinity and efficacy profile were comparable to pagoclone with the exception that efficacy at the α1 subtype was considerably greater for 5′-hydroxy pagoclone compared with the parent.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
the plasma and brain samples derived from the elevated plus maze assay, the major metabolite of pagoclone, 5′-hydroxy pagoclone, was present at 10–20-fold higher concentrations relative to the parent compound.
MAJOR
CSF
|
||
|
PARENT -> METABOLITE ACTIVE |
The major metabolite of pagoclone, 5′-hydroxy pagoclone, was present at 10–20-fold higher concentrations relative to the parent compound.
PLASMA
|
